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Abstract 
Purpose: Surgical arteriovenous fistula (AVF) or graft (AVG) is preferred to a central venous 
catheter for dialysis access. Surgical access may suffer thrombosis early after placement and 
systemic anticoagulation during surgical access formation may increase patency rates but would 
be expected to increase bleeding related complications.  A systematic review and meta-analysis 
of randomised controlled trials was conducted to examine the impact of systemic anticoagulation 
on access surgery perioperative bleeding and patency rates. 
Methods: We included randomised controlled trials testing systemic anticoagulation during 
access formation versus a control group without systemic anticoagulation reporting bleeding 
complications and access patency. Medline, Embase, CENTRAL and CINAHL were searched 
up to March 2015.  Risk of bias was assessed using the Cochrane risk of bias tool and the 
JADAD score. Meta-analysis was performed using Cochrane Revman software. 
Results: Searches identified 445 reports of which four randomised studies involving 411 
participants were included. Three studies pertained to AVF only and one included both AVF and 
AVG. Systemic anticoagulation led to increased bleeding events in all access (4 trials; RR 7.18; 
CI, 2.41to 21.38; p<0.001). Patency was not improved for all access (4 trials; RR, 0.64; CI, 0.37 
to 1.09;P=0.10) but was improved when AVF analysed alone (3 trials; RR, 0.57; CI, 0.33 to 
0.97; p=0.04). 
Conclusions: The use of intraoperative systemic anticoagulation during access formation is 
associated with a highly significant increased risk of bleeding related complications . A 
significant improvement in AVF patency was seen though not when AVF and AVG were 
analysed together. 
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 Introduction 
The use of autologous arteriovenous fistulae for the purpose of haemodialysis was first described 
in 1966 by Brescia et al(1) and the arteriovenous fistula (AVF) is now recognised as the gold 
standard for maintenance haemodialysis due to superior long term patency, reduced rates of 
complications and superior cost effectiveness in comparison to grafts or central lines(2). An 
alternative surgical access may be formed with interposition prosthetic arteriovenous graft AVG 
where autologous vein is not available as a conduit. Least preferable access is via a tunnelled 
central venous catheter due to high rates of infective complications(3) 
 
Surgical access formation results in a number of failures due to thrombosis and many strategies 
have been researched in an attempt to minimise the loss of access and the lifesaving dialysis they 
provide (4, 5). The use of systemic anticoagulation during access formation surgery has been 
suggested as one such strategy to improve patency rates(6), however there is the potential of an 
increased risk of peri-operative bleeding and/or haematoma formation. The aim of this report is 
to review the evidence regarding outcomes of access surgery with and without use of systemic 
anticoagulation with specific reference to rates of bleeding related complications and access 
patency.  
 
Methods 
A systematic review of randomised clinical trials (RCTs) comparing access procedures with and 
without intraoperative systemic anticoagulation was performed. The Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used for reporting of  
search results(7). The methodological quality of the studies was determined using both the 
Cochrane Collaboration bias tool(8) and the Jadad scoring system(9).  
 
Search Strategy 
Systematic review was performed using MEDLINE and EMBASE, CENTRAL and CINAHL. 
The search strategy aimed to include any RCT which compared access formed with and without 
intraoperative systemic anticoagulation therapy. Search terms used were: 
 (dialysis or haemodialysis or hemodialysis or hemofiltration or haemofiltration or 
(hemodiafiltration or haemodiafiltration)AND (Arteriovenous Fistula or Arteriovenous Shunt or 
vascular access or venous access or (fistula* or avf* or graft or shunt)) AND systemic (heparin 
or anticoagulant or anti-coagula* or anticoagula*) AND Surgery. 
 Search methods included all indexed citations of any language from the databases beginning to 
March 2015. Results were limited to human subjects only. In addition, references within 
identified or related publications were hand searched to identify any additional studies.  
Inclusion criteria 
Studies were eligible for inclusion if they fulfilled the following criteria. 
• Studies including adults requiring formation of arteriovenous graft or autologous fistulae 
as vascular access for haemodialysis.  
• Randomised controlled trials and quasi-RCTs comparing intraoperative systemic 
anticoagulation with control group not receiving systemic anticoagulation 
• No limits were placed on time, location or language of the study.  
Outcomes 
The primary outcome was the rate of bleeding related complications of surgery (either visible 
postoperative bleeding or haematoma formation) following access formation. The secondary 
outcomes were the rate of early failure in access formed and rates of ongoing patency (as 
primary, secondary and functional patency).  
Data extraction 
Assessment for inclusion and data extraction were carried out by two independent reviewers (PS, 
TC) and any disagreements were resolved by consensus and a third author (GS).  For Meta-
analysis, data were entered into and analysed using Cochrane RevMan software (RevMan 5.3. 
The Cochrane Collaboration, Copenhagen) and dichotomous outcomes presented as risk ratios 
(RR) with 95% confidence intervals (CI). 
Results 
Literature search 
Systematic review of the literature identified 445 potential studies, of which 442 were 
discounted as ineligible after title and abstract review. After full text review of the remaining 3 
papers, 3 were eligible for systematic inclusion (10-12). In addition, 1 paper was included 
following manual search of references of included reports (13). 
Included studies 
Our analysis included four trials (10-13), all of which utilised anticoagulation with systemic 
heparin during access formation. A total of 411 patients were included across four trials. Three 
trials included only autologous AVF(11-13) with one trial incorporating both AVF and 
AVG(10).  Summary data including anticoagulation employed, control regime and outcomes in 
included studies are reported in table 1. No study reported any measurement of anticoagulation 
effects using laboratory studies.  
Risk of Bias 
No study protocols were available for the included trials. On the basis of information published 
within reports the methodological quality of the trials, as shown in table 2, was generally low 
with Jadad scores of one or two.  
Bleeding related complications 
All papers reported on rates of perioperative bleeding or postoperative haematoma formation. 
Meta-analysis of data for AVF and AVG together(10-13) showed a significant effect towards 
higher incidence of bleeding related complications with the use of systemic heparin (p<0.001; 
RR 7.18; CI, 2.41to 21.38). Data included is shown in figure 1. 
Separate analysis of the three trials including only autologous AVF(11-13) still indicated a 
higher rate of bleeding related complications though this was less marked than for all access 
(p=0.02: RR4.83; CI, 1.28 to 18.19). 
Insufficient detail was present in the report which included AVG to allow analysis of AVGs as a 
separate sub group.  
 
Patency 
Primary patency was assessed at different time points between included studies. Two papers 
reported 30 day primary patency (10, 12); one reported 14 day (13) and one 44 day follow up 
(11). One paper also reported three month functional patency (10).  
No detailed survival meta-analysis was feasible due to heterogeneous follow up regimes reported 
and lack of reported data. A simple dichotomous meta-analysis of the rate of failure events prior 
to first follow up suggests that effects of systemic heparin on early patency favoured heparin but 
the result was not statistically significant when all access types (AVF and AVG) were analysed 
(P=0.10; RR, 0.64; CI,  0.37 to 1.09). Data included is shown in figure 2.  
Separate analysis of the three trials including only autologous AVF(11-13) did reach statistical 
significance for improved patency at first follow up (p=0.04: RR, 0.57; CI, 0.33 to 0.97). 
Insufficient detail was present in the report which included AVG to allow analysis of AVGs as a 
separate sub group.  
 
 
Discussion 
This systematic review demonstrates that there is randomised controlled evidence in the current 
literature regarding the use of systematic anticoagulation during AVF surgery. Although the 
outcomes reported in all included studies were related to bleeding complications of surgery and 
early primary patency of AVF formed, the conclusions were contradictory between reports.  
 
All included studies reported increased rates of bleeding complications with the use of systemic 
heparin though this was reported to be statistically significant in only two studies (10, 11). Meta-
analysis of this data suggested a highly significant increase in bleeding related complications 
with the use of intra-operative systemic anticoagulation with heparin for all access surgery 
(p=0.002). This effect was also evident, though less significant when only autologous AVF were 
included in the analysis(p=0.02). 
An increase in bleeding related complications is to be expected in the presence of systemic 
heparin administration and studies reported mainly self-limiting or relatively minor bleeding 
events only. A minority of the participants receiving systemic heparin subsequently suffered 
more significant complications such as transfusion (4 transfusions in 3 participants(10)) or 
reoperation for evacuation of haematoma (1 reoperation (12)). Only one report stated whether 
the haematomas which occurred in the patients receiving systemic anticoagulation with heparin 
had any direct effect on early patency due to compression of AVF (three AVF lost patency with 
haematoma development(10)). 
 The above bleeding risks may be deemed acceptable if a clear benefit in terms of patency were 
to be apparent with systemic anticoagulation.Studies reported no significant difference in 
primary patency at 30 days (10, 12) and 6 weeks (11) and no difference in functional patency at 
3 months (10). Only 1 of the 4 included studies reported a significant increase in patency with 
intraoperative systemic heparin administration as measured at 2 weeks post procedure (13). 
Heparin administered intravenously during AVF formation would not be expected to remain 
present within a participant’s blood stream much beyond a period of 2 hours(14). The potential 
action for improved patency with intraoperative systemic heparin may therefore be the 
prevention of thrombosis in the immediate post-operative period when flow may be reduced due 
to localised inflammatory swelling of tissues and spasm in the vessels. However, the only study 
that reported a significant improvement in patency with systemic heparin was also the only one 
to report patency within 24 hours of procedure, and found no significant difference in patency 
between groups at that time point (P=0.609)(13). The protective effects of heparin against loss of 
patency which this study reports would therefore appear to have occurred beyond 24 hours post 
procedure during a period in which the heparin was no longer active, further confusing the 
conclusions drawn by individual studies and interpretation of the trend demonstrated in this 
limited meta-analysis. 
Meta-analysis of dichotomous outcomes for AVF patency at early follow up was performed due 
to the lack of detailed survival information in reports and accessible individual patient data. The 
analysis of access patency rates at early follow up shows a non-significant trend in favour of 
improved early primary patency with intraoperative systemic heparin administration when all 
access were included in the analysis (Figure 3). Analysis of data for autologous AVF only(11-
13) did show a just significant improvement in patency at first follow up (p=0.04) suggesting 
that systemic anticoagulation with heparin during AVF formation may be of some benefit to 
ongoing patency. 
There are some clear limitations to this review and meta-analysis as the studies were generally 
small and most had methodological limitations suggesting a risk of bias. With the exception of 
one study (10) follow up periods and outcomes included in reports were very limited. The doses 
of anticoagulation utilised were not consistant between trials included. Finally, no study reported 
monitoring of the baseline coagulation studies or the effects of administered anticoagulation in 
the intervention group with laboratory studies. This is important as uraemic patients are already 
at elevated risk of bleeding due to the so called “uremic thrombopathy”, a multifactorial 
condition brought about by platelet dysfunction, platelet-endothelial interaction defects, 
increased prostacyclin and nitric oxide levels and anaemia with a low haematocrit(15). Without 
monitoring it is difficult to ascribe all bleeding related complications to the use of heparin or to 
know if appropriate doses were utilised in already compromised patients.  
The use of intraoperative systemic heparin during AVF formation is associated with a scarcely 
significant improvement in patency at early follow up. Though the very highly significant 
increased risk of bleeding related complications with interoperative systemic heparin use, 
occasionally requiring transfusion or re-operation, would appear to outweigh the small potential 
benefit to patency. No benefit in patency was shown when AVG and AVF were analysed 
together though the bleeding risk remained significant. Accepting the limitations of this review, 
current evidence does not appear support the use of systemic anticoagulation during access 
surgery. 
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Table 1 Summary of included studies and results (ND = Not described, LA = Local anaesthetic) 
Study Sampl
e size 
Interventio
n 
N= Autologo
us or 
prosthetic 
access 
Anaesthes
ia 
Mea
n 
age 
Male 
Gende
r (%) 
Bleedin
g 
events 
Failur
e 
within 
30 
days 
(%) 
D’Ayal
a et al 
(2008) 
 
 
 
115 
5000U 
Systemic 
Heparin 
57  
Mixed 
 
 
LA with 
sedation 
60  57 13 
(23%) 
9 
(16%) 
at 30 
days 
Heparinise
d Saline 
58 62  53 1(1.8%) 8 
(14%) 
at 30 
days 
Bhomi 
et al 
(2008) 
 
 
50 
5000U 
Systemic 
Heparin 
25  
Autologo
us 
 
LA 
48 56 6 (24%) 1 
(4%) 
at 6 
weeks 
Heparinise
d Saline 
25 50 52 0 (0%) 2 
(8%) 
at 6 
weeks 
Ravari 
et al 
(2008) 
 
 
198 
5000U 
Systemic 
Heparin 
96  
Autologo
us 
 
ND 
48 62 3(3%) 14 
(15%) 
at 2 
weeks 
ND 10 49 62 1 (1%) 26 
2 (26%) 
at 2 
weeks 
Wang 
et al 
(2010) 
 
 
48 
75units/K
G Heparin 
26  
Autologo
us 
 
ND 
52 54 3 (12%) 
2 
(8%) 
at 30 
days 
ND 22 50 45 1 (5%) 3 
(14%) 
at 30 
days 
 
 
Table 2 Summary assessment of risk of bias in the studies identified 
Study Random 
Sequence 
Generation 
(selection 
bias) 
Allocation 
Concealment 
(selection 
bias) 
Blinding 
(performance 
bias and 
detection 
bias) 
Incomplete 
outcome 
data 
(attrition 
bias) 
Selective 
reporting 
(reporting 
bias) 
Other 
Bias 
Jadad 
score 
D’Ayala 
(2008) 
Unclear Unclear Unclear Low Unclear Low 2 
Bhomi 
(2008) 
Unclear Unclear Unclear Low Unclear Low 2 
Ravari 
(2008) 
Low High Unclear Unclear Unclear Low 1 
Wang 
(2010) 
Unclear Unclear Unclear Low Unclear Low 2 
 
 
 Figure 1. Forrest plot demonstrating significantly increased risk of bleeding related 
complications with systemic anticoagulation use in all access types 
 
Figure 2. Forrest plot demonstrating no significant difference in risk of loss of patency at first 
follow up in all access types 
